生命科学资讯

Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition

Galux raises $29M Series B; CSL teams up with Memo

#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%

Takeda, Iambic sign multiyear R&D deal for AI drug discovery

Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages

Lilly returns to Innovent to partner on cancer and immune diseases

Hims says it will stop selling GLP-1 pill, after legal pressure from US

#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS

The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more

US calls for DOJ investigation of Hims over GLP-1 drugs

TrumpRx launch falls flat for some, citing generic access

HHS drops legal fight over blocked 340B rebate pilot

Orphan drug tweak in US spending bill will make life easier for the FDA

Agomab, SpyGlass cap biggest week for biotech IPOs since 2021

Biogen CEO says Alzheimer's drug Leqembi on track for continued growth

UniQure pauses higher doses in Fabry study; Aro shares Pompe data

Geoff McDonough's big plans for NodThera's NLRP3; Enhertu leader steps down at Daiichi

Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosis

Post-Hoc Live: Analyzing the Novo vs. Hims GLP-1 showdown

Illumina bets on healthcare after Trump administration's NIH funding disruptions